



## ERRATUM

# Erratum to “Functional roles of the glial glutamate transporter (GLAST) in emotional and cognitive abnormalities of mice after repeated phencyclidine administration” [European Neuropsychopharmacology (2019) 29, 914–924]



Mizuki Uchida<sup>a</sup>, Hirotake Hida<sup>a</sup>, Kentaro Mori<sup>a</sup>, Akira Yoshimi<sup>a</sup>, Shinji Kitagaki<sup>b</sup>, Kiyofumi Yamada<sup>c</sup>, Yuichi Hiraoka<sup>d</sup>, Tomomi Aida<sup>d</sup>, Kohichi Tanaka<sup>d</sup>, Norio Ozaki<sup>e</sup>, Yukihiro Noda<sup>a,e,\*</sup>

<sup>a</sup>Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Japan

<sup>b</sup>Department of Medical Chemistry, Graduate School of Pharmacy, Meijo University, Nagoya, Japan

<sup>c</sup>Department of Neuropsychopharmacology and Hospital Pharmacy, Graduate School of Medicine, Nagoya University, Nagoya, Japan

<sup>d</sup>Laboratory of Molecular Neuroscience, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

<sup>e</sup>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan

Received 15 July 2019; accepted 18 July 2019

The publisher regrets a number of errors, as below. The Publisher sincerely apologises for any inconvenience caused.

- NMDA should read in full ‘N-methyl-D-aspartate’
- The following sentence in Figure legend 2 should read: The spontaneous activity was measured over 60 min. Values are mean  $\pm$  S.E.M. (SAL-administered GLAST + / + mice:  $n = 6$ , SAL-administered GLAST + / – mice:  $n = 6$ , PCP-administered GLAST + / + mice:  $n = 6$ , and PCP-administered GLAST + / – mice:  $n = 6$ ).

DOI of original article: [10.1016/j.euroneuro.2019.06.005](https://doi.org/10.1016/j.euroneuro.2019.06.005)

\* Corresponding author at: Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Japan.

E-mail address: [ynoda@meijo-u.ac.jp](mailto:ynoda@meijo-u.ac.jp) (Y. Noda).

<https://doi.org/10.1016/j.euroneuro.2019.07.140>

0924-977X/© 2019 Elsevier B.V. and ECNP. All rights reserved.

• Funding section should read: This study was supported by Grants-in-Aid for Scientific Research C (grant numbers 24590219, 26460240, 16K08421, 17K10325) from Japan Society for the Promotion of Science; Japan, the Private University Research Project from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan, Japan Agency for Medical Research and Development (AMED) under grant numbers JP18dm0107087 & JP18dm0207005; Japan, The Adaptable and Seamless Technology Transfer Program through Target-Driven R&D from Japan Science and Technology Agency (grant number AS251Z03018); Japan, Meijo University Research Institute Grant; Japan, the Smoking Research Foundation Grant for Biomedical Research (SRF); Japan.

• Conflict of interest statement should read: Dr. Noda has received research support or speakers' honoraria from Sumitomo Dainippon Pharma, Janssen Pharmaceuticals, Otsuka Pharmaceutical, and Kyorin Pharmaceutical. Dr. N. Ozaki has received research support or speakers' honoraria from, or has served as a consultant to Astellas, Sumitomo Dainippon, Eisai, Eli Lilly, Janssen, Meiji Seika Pharma, Mochida, MSD, Nihon Medi-Physics, Ono, Kyowa Hakko Kirin, Novartis, Otsuka, Pfizer, Takeda, Taisho, Mitsubishi Tanabe, Tsumura, and KAITEKI.